Science that works
with your body.
We are with you during the full personalized mRNA vaccine process with the right expertise at the right moment of care.
WHAT WE DO
We bring coordinated expertise across tumor analysis, AI‑powered vaccine design, GMP manufacturing, regulatory navigation, and clinical administration. Our team’s decades of combined experience help guide you through every step of the personalized mRNA process with clarity, care, and precision.
Tailored Scientific Rigor
We walk beside you with a multidisciplinary team to gather the deep sequencing data needed, design your personalized mRNA vaccine, and guide clinical decisions. You can expect strict quality standards and applied expertise at every step.
True Personalized Medicine
Your care is centered around you. We guide you through each step with clear communication, thoughtful support, and a team dedicated to making your experience feel informed, personal, and grounded in your unique biology.
Manufacturing, Regulatory
& Custom Monitoring
We navigate the manufacturing and regulatory steps to meet the requirements needed to deliver a therapy designed for your tumor. Custom monitoring provides insight into your immune response to your personalized vaccine.
Experienced in
Dosing Patients
We have direct clinical experience administering personalized mRNA vaccines. Our experience means you have a partner who guides each step with clarity and confidence.
OS PLATFORM | OUR TECHNOLOGY
We’re building more than vaccines. We’re building the operating system behind them.
Echo’s operating system addresses three core challenges of personalized cancer vaccines:
design, manufacturing, and regulatory, through a single integrated loop from tissue to dose that improves with each cycle.
WORKING WITH YOU
Echo Immune brings together a multidisciplinary team that handles everything from advanced genetic sequencing to monitoring and reporting results, supporting your care from start to finish.
PHASE 1
Genetic Data Discovery
Our clinical team helps track down and process your tumor tissue. It ensures you have full genome and RNA sequencing to identify the tumor‑specific changes that guide your personalized mRNA vaccine.
PHASE 2
Uncover Your Immune Targets
Our genomic experts analyze your sequencing data with AI models to identify the vaccine epitopes, which are the parts of each tumor‑specific target that your immune system can learn to recognize through your personalized mRNA vaccine.
PHASE 3
Manufacture Your Vaccine
Our team handles FDA requirements for your vaccine. A GMP‑certified lab produces, vials, and releases it. We coordinate with a participating clinic in your region to keep treatment timing aligned.
PHASE 4
Vaccine Administration & Monitoring
Start your Treatment
Your treating physician administers your vaccine doses at the closest coordinated clinic. You start building immunity with the first dose, and over six months, your immune system learns to recognize the selected epitopes.
Personalized Immune Monitoring
We track your immune response to your tumor targets with an assay tailored to your biology. Our team collects safety data during treatment and works with your care team to support a personalized medicine approach with regulatory oversight.
FAQs
-
Our personalized mRNA vaccines are for patients with solid tumors. You, a family member, or your physician can begin the request, and we offer a consultation to help you explore whether Echo is right for your care.
-
mRNA and lipid nanoparticle technology have been used safely around the world. In personalized cancer vaccine studies, serious side effects have been uncommon, with most people experiencing only mild, short‑term effects like fatigue, fever, or injection‑site soreness.
Sahin U, et al. Nature. 2017: A personalized mRNA cancer vaccine in melanoma showed strong immune activation and was generally well‑tolerated.
Hu Z, et al. Cell. 2021: A personalized neoantigen vaccine across multiple solid tumors was safe and produced targeted immune responses. -
No. Personalized mRNA cancer vaccines are not FDA-approved yet. Moderna, Merck, and BioNTech have Phase 3 trials underway, and the goal is full regulatory approval. Echo Immune provides individually manufactured therapeutic vaccines that physicians can administer under existing medical frameworks such as compassionate use. This is still an experimental therapy.
-
Yes, we are the first privately held company to dose a patient. We began treating our first patient in June 2026. We are closely monitoring this patient, and early testing shows an immune response, including T‑cells specific to the vaccine. This is an experimental therapy, and immune activation is an important first step. We continue to gather monitoring data carefully and responsibly.
-
A free consultation can help you understand if this approach fits your medical needs. We review your history, current treatment plan, and goals to help you see whether Echo Immune’s personalized mRNA platform is the right step in your mRNA journey.
Getting started
with Echo.
Thank you for your interest in Echo Immune. We welcome your inquiry by completing the form, and we'll be in touch shortly.